ANTON KOOPMAN: Open Payments
NPI 1538182035 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$848 in 39 payments from 15 companies in 2025. Trend: 2023 $915 · 2024 $870 · 2025 $848
Food & beverage: $848
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $322 |
| Lilly USA, LLC | 6 | $88 |
| ABBVIE INC. | 5 | $85 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Novo Nordisk Inc | 4 | $65 |
| Abbott Laboratories | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Avvisto Therapeutics, LLC | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: FARXIGA, Auvelity, VRAYLAR, MOUNJARO, FREESTYLE LIBRE 3, Wegovy, TRELEGY ELLIPTA, CYCLOSET.
Industry payments across IN — which companies pay providers there.
